000125421 001__ 125421
000125421 005__ 20240228143306.0
000125421 0247_ $$2doi$$a10.1007/s13277-015-4089-4
000125421 0247_ $$2pmid$$apmid:26383527
000125421 0247_ $$2ISSN$$a0289-5447
000125421 0247_ $$2ISSN$$a1010-4283
000125421 0247_ $$2ISSN$$a1423-0380
000125421 0247_ $$2altmetric$$aaltmetric:4531191
000125421 037__ $$aDKFZ-2017-01551
000125421 041__ $$aeng
000125421 082__ $$a570
000125421 1001_ $$0P:(DE-HGF)0$$aAkram, Israa G$$b0$$eFirst author
000125421 245__ $$aThe chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.
000125421 260__ $$aBerlin$$bSpringer$$c2016
000125421 3367_ $$2DRIVER$$aarticle
000125421 3367_ $$2DataCite$$aOutput Types/Journal article
000125421 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524211331_4838
000125421 3367_ $$2BibTeX$$aARTICLE
000125421 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125421 3367_ $$00$$2EndNote$$aJournal Article
000125421 520__ $$aC-C chemokine receptor type 1 (CCR1) and chemokine C-C motif receptor-like 2 (CCRL2) have not yet been sufficiently investigated for their role in colorectal cancer (CRC). Here, we investigated their expression in rat and human CRC samples, their modulation of expression in a rat liver metastasis model, as well as the effects on cellular properties resulting from their knockdown. One rat and five human colorectal cancer cell lines were used. CC531 rat colorectal cells were injected via the portal vein into rats and re-isolated from rat livers after defined periods. Following mRNA isolation, the gene expression was investigated by microarray. In addition, all cell lines were screened for mRNA expression of CCR1 and CCRL2 by reverse transcription polymerase chain reaction (RT-PCR). Cell lines with detectable expression were used for knockdown experiments; and the respective influence was determined on the cells' proliferation, scratch closure, and colony formation. Finally, specimens from the primaries of 50 patients with CRC were monitored by quantitative RT-PCR for CCR1 and CCRL2 expression levels. The microarray studies showed peak increases of CCR1 and CCRL2 in the early phase of liver colonization. Knockdown was sufficient at mRNA but only moderate at protein levels and resulted in modest but significant inhibition of proliferation (p < 0.05), scratch closure, and colony formation (p < 0.05). All human CRC samples were positive for CCR1 and CCRL2 and showed a significant pairwise correlation (p < 0.0004), but there was no correlation with tumor stage or age of patients. In summary, the data point to an important role of CCR1 and CCRL2 under conditions of organ colonization and both chemokine receptors qualify as targets of treatment during early colorectal cancer liver metastasis.
000125421 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000125421 588__ $$aDataset connected to CrossRef, PubMed,
000125421 650_7 $$2NLM Chemicals$$aRNA, Messenger
000125421 650_7 $$2NLM Chemicals$$aReceptors, CCR
000125421 7001_ $$0P:(DE-HGF)0$$aGeorges, Rania$$b1
000125421 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000125421 7001_ $$0P:(DE-HGF)0$$aAdwan, Hassan$$b3
000125421 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b4$$eLast author$$udkfz
000125421 773__ $$0PERI:(DE-600)1483579-4$$a10.1007/s13277-015-4089-4$$gVol. 37, no. 2, p. 2461 - 2471$$n2$$p2461 - 2471$$tTumor biology$$v37$$x1423-0380$$y2016
000125421 909CO $$ooai:inrepo02.dkfz.de:125421$$pVDB
000125421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000125421 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000125421 9141_ $$y2016
000125421 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000125421 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125421 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125421 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125421 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125421 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTUMOR BIOL : 2015
000125421 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125421 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125421 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125421 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125421 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125421 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125421 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000125421 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lToxikologie und Chemotherapie$$x0
000125421 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000125421 980__ $$ajournal
000125421 980__ $$aVDB
000125421 980__ $$aI:(DE-He78)G401-20160331
000125421 980__ $$aI:(DE-He78)C060-20160331
000125421 980__ $$aUNRESTRICTED